Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Authors
Keywords
-
Journal
LEUKEMIA
Volume 27, Issue 8, Pages 1707-1714
Publisher
Springer Nature
Online
2013-01-31
DOI
10.1038/leu.2013.29
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies.
- (2017) P. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
- (2012) Ravi Vij et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
- (2012) M. Alsina et al. CLINICAL CANCER RESEARCH
- The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
- (2012) M A Dimopoulos et al. LEUKEMIA
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
- (2011) J. Yang et al. DRUG METABOLISM AND DISPOSITION
- Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature
- (2011) D. J. Araten et al. HAEMATOLOGICA
- Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients
- (2010) Lene Meldgaard Knudsen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
- (2009) Sundar Jagannath et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
- (2009) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
- (2008) A. A. Argyriou et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now